Celixir publishes positive study results for potential cancer gene therapies showing cancer cell reduction in colon and breast cancer cell lines
- Promising cancer gene therapy programme using small interfering RNA (siRNA)
- Data from in vitro study published in PLOS journal
Stratford-upon-Avon, UK, 13 May 2019 – Celixir, a privately-owned company discovering and developing life-saving advanced therapies, is pleased to announce the publication of in vitro study results highlighting the potential of its novel cancer gene therapies targeting solid tumours. Celixir is developing a new gene therapy plaform using small interfering RNA (siRNA).
The study showed that all four of Celixir’s siRNA molecules reduced the number of live colon and breast cancer cells in vitro by approximately 50% within seven days by inhibiting their proliferation and increasing apoptosis (programmed cell death). The study was published in PLOS and can be viewed on the journal’s website.
Celixir is developing four siRNA molecules with the potential to be utilised as novel cancer gene therapies (programme CLXR-005). siRNA molecules are capable of blocking intracellular cancer targets that conventional medicines, such as antibodies and small molecules, typically cannot. All four of Celixir’s siRNA molecules block the novel intracellular cancer target, STAT6, which is expressed in hard to treat and drug-resistant cancers, such as colon, breast, lung, pancreatic and prostate cancers, and is typically associated with an increased malignancy and poor prognosis. The siRNA molecules have now progressed to in vivo studies.
Dr. Lee Chapman, Head of Oncology at Celixir, said: “These early results are promising and highlight the potential of Celixir’s oncology gene therapy pipeline to aid in the treatment of two of the most serious cancers, colon cancer and breast cancer.”
Ajan Reginald, Chief Executive Officer of Celixir, said: “We are encouraged by this initial data, which exemplifies the potential of siRNA as an anti-cancer technology. Our siRNA molecules block STAT-6, which is highly expressed in hard to treat, drug-resistant cancers and not typically targeted by antibodies or small molecules. This is the first publication from our exciting oncology portfolio of novel cell and gene therapies targeting drug-resistant targets.”
For more information, please contact:
Ajan Reginald, CEO
+44 1789 269 838
Consilium Strategic Communications
Mary Jane Elliott / Sukaina Virji / Angela Gray
+44 (0)20 3709 5700
Celixir is a privately owned UK biotechnology company that discovers and develops life-saving and life-altering advanced therapies for patients with the greatest medical need. Celixir, founded in 2009, is made up of a world class team of scientists and biopharmaceutical executives, led by Nobel Laureate Professor Sir Martin Evans and former Roche Global Head of Emerging Technologies, Ajan Reginald. Celixir’s unique platform technology allows it to adopt an ‘off-the-shelf’ approach to deliver cell therapies to patients. The Company has a partnership with Daiichi Sankyo in which the Japanese pharmaceutical company undertakes all development, regulatory and commercial activities for Celixir’s immunomodulatory progenitor cells in Japan. Celixir retains worldwide rights outside of Japan and global manufacturing responsibilities.